Next, we evaluated the efficacy of FB23-2 alone and in combination with talazoparib in a ccRCC patient–derived xenograft (PDX, RCC054) established from a VHL-deficient ccRCC colon metastasis (35). The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.